Abstract
Exocrine pancreatic function can be assessed by determining the recovery in urine of p-aminobenzoic acid (PABA) following the oral administration of (N-benzoyl-L-tyrosylamino)benzoic acid (bentiromide). However, misleadingly abnormal results often occur in patients with abnormal intestinal, liver and renal function. Co-administration of 14C-PABA and the determination of the ratio of the recoveries of PABA to 14C-PABA, the PABA excretion index (PEI), has been used to eliminate these misleading results. Unfortunately, this has the disadvantage of exposing patients to radioactivity. We report the development and optimization of a modified test in which anthranilic acid, the ortho isomer of aminobenzoic acid, is substituted for the radiolabelled PABA. PABA and anthranilic acid in urine are determined by a C18 reversed-phase HPLC method. Peak detection is carried out at 254 nm. The method is specific for PABA and anthranilic acid, precise and fairly rapid. The PABA excretion index values in patients with pancreatic steatorrhoea (0.18–0.43) determined using the new liquid chromatographic method were clearly separated from those in healthy controls (0.63–1.14).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
